Indole-3-carbinol suppresses NF-ÎºB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells by Safa, M. et al.
RESEARCH ARTICLE
Indole-3-carbinol suppresses NF-κB activity and stimulates
the p53 pathway in pre-B acute lymphoblastic leukemia cells
Majid Safa & Behnaz Tavasoli & Rima Manafi &
Fatemeh Kiani & Meysam Kashiri & Saber Ebrahimi &
Ahmad Kazemi
Received: 6 October 2014 /Accepted: 30 December 2014 /Published online: 15 January 2015
# International Society of Oncology and BioMarkers (ISOBM) 2015
Abstract B cell precursor acute lymphoblastic leukemia
(BCP-ALL) is the most common type of cancer in children.
Dramatic improvements in primary therapy for childhood
ALL have led to an overall cure rate of 80 %, providing op-
portunities for innovative combined-modality strategies that
would increase cure rates while reducing the toxic side effects
of current intensive regimens. In this study, we report that
indole-3-carbinol (I3C), a natural phytochemical found in cru-
ciferous vegetables, had anti-leukemic properties in BCP-
ALL NALM-6 cells. I3C induced cell growth inhibition by
G1 cell cycle arrest and triggered apoptosis in a dose- and
time-dependent manner. p53, p21, and Bax proteins showed
increased expression after I3C treatment. Real-time PCR anal-
ysis of pro-apoptotic p53 target genes revealed up-regulation
of PUMA, NOXA, and Apaf-1. I3C also suppressed constitu-
tive nuclear factor-κB (NF-κB) activation and inhibited the
protein expression of NF-kappa B-regulated antiapoptotic
(IAP1, Bcl-xL, Bcl-2, XIAP) and proliferative (c-Myc) gene
products. Coadministration of I3C with the topoisomerase II
inhibitor, doxorubicin, potentiates cytotoxic effects compared
with either agent alone. Apoptosis induction by the drug
combination was associated with enhanced caspase-9 activa-
tion and PARP cleavage. Furthermore, I3C abolished
doxorubicin-induced NF-κB activity as evidenced by de-
creased nuclear accumulation of p65, inhibition of IκBα phos-
phorylation and its degradation, and decreased NF-κB DNA-
binding activity. Western blot analysis revealed that
doxorubicin-induced Bcl-2 protein expression was inhibited
by I3C. Overall, our results indicated that using nontoxic
agents, such as I3C, in combination with anthracyclines might
provide a new insight into the development of novel combi-
nation therapies in childhood BCP-ALL.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
childhoodmalignancy accounting for almost 30% of pediatric
cancers. It has a peak incidence at 2 to 5 years of age, but also
occurs, albeit with low incidence, in adults and the elderly [1].
Despite high cure rates for ALL, resistance to treatment and
disease relapse remain a significant problem. Understanding
the mechanisms by which chemoresistance can occur is there-
fore important for developing novel therapeutic approaches
aiming to improve patient survival [2, 3]. Leukemic cells ex-
hibit uncontrolled proliferation mostly due to aberrantly reg-
ulated cell survival and apoptosis signaling pathways [4].
TP53 is the most common tumor suppressor gene mutated in
all human cancers which is associated with poor prognosis
and drug resistance [5]. Interestingly, in pediatric ALL, the
incidence of TP53 mutation is considerably low [6], reflecting
the fact that wild-type p53 harboring ALL cells can be
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targeted by agents that activate p53 signaling pathway [7]. In
contrast to activation of p53, which is associated with the
induction of apoptosis, stimulation of nuclear factor-κB
(NF-κB) has been shown to promote resistance to apoptosis
[8, 9]. NF-κB consists of p50 and p65 heterodimer retained in
the cytoplasm by inhibitory proteins called IκBs. In response
to many stimuli, IκB kinase (IKK) is activated, leading to
IκBα phosphorylation, ubiquitination, and degradation by
the proteasome. The liberated p50-p65 complex then translo-
cates to the nucleus, binds to its consensus sequence within
the promoter of NF-kB target genes, and regulates gene tran-
scription [10, 11]. A group of antiapoptotic genes, including
Bcl-xL, cIAP1, cIAP2, XIAP, Bcl-2, c-FLIP, and TRAF-2,
can be up-regulated by NF-κB, underlining its importance
on cell death in cancer cells [12, 13]. Persistent and prolonged
activation of NF-κB has been observed in several types of
cancer where it is believed to induce gene products that allow
these cells to evade apoptosis [14, 15]. Constitutive NF-κB
activation occurs in over 90 % of childhood ALL tumors and
strongly suggests a critical role of this factor for leukemia cell
survival either by blocking apoptosis or by enhancing prolif-
eration [16]. Thus, there are compelling reasons to believe that
subverting NF-κB function would be an effective strategy to
restore or enhance apoptosis in ALL cells. Much evidence
indicates that various natural compounds exhibit an anticancer
effect through perturbing multiple cellular signaling pathways
[17]. Indole-3-carbinol (I3C), a natural compound present in
cruciferous vegetables such as broccoli and cabbage, is a
promising anticancer phytochemical [18]. In various cancer
cells, I3C has exhibited anticancer effects, including cell cycle
inhibition, apoptosis, and decreasing tumor invasion through
modulation of cellular signals such as NF-κB, p53, Akt, and
JNK pathways [19–21]. However, the effect of I3C on B cell
precursor acute lymphoblastic leukemia (BCP-ALL) cells, the
most predominant subtype in all age groups of ALL, has not
yet described. In the present study, we investigated the effects
and the molecular mechanism of I3C on growth and apoptosis
in BCP-ALL-derived cell line NALM-6. We show that treat-
ment of NALM-6 cells with I3C induces apoptosis in a dose-
and time-dependent manner. In addition, I3C down-regulates
the expression of antiapoptotic NF-κB target genes and acti-
vates p53 signaling pathway. Cotreatment of I3C with doxo-
rubicin dramatically increased apoptosis in NALM-6 cells.
Material and methods
Cell culture
NALM-6 cells (human B cell precursor acute lymphoblastic
leukemia cell line) were grown in suspension in RPMI medi-
um supplemented with 2 mM L-glutamine, 10 % FBS,
100 units/ml penicillin, and 100 μg/ml streptomycin in a
humidified 5 % CO2 incubator at 37 °C under standard cell
culture conditions.
Cell proliferation assay
The effect of various concentrations of I3C on metabolic ac-
tivity of NALM-6 cells was assessed by the MTTcolorimetric
method. MTT is reduced to an insoluble formazan dye by
mitochondrial enzymes associated with metabolic activity.
Actively proliferating cells increase their metabolic activity
while cells exposed to cytotoxic drugs will have decreased
activity. Briefly, exponentially growing cancer cells were
seeded into a 96-well culture plate at a density of 10×103
cells/well and incubated with various concentrations of I3C
for 24 and 48 h. After removing the medium, cells were incu-
bated with MTT solution (5 mg/ml in PBS) for 4 h and the
resulting formazan was solubilized with DMSO (100 μl). The
absorbance of each well was measured at 570 nm in an ELISA
reader.
Sub-G1 DNA content analysis
Apoptotic cells were detected using PI staining of I3C-treated
cells followed by flow cytometry to detect the so-called sub-
G1 peak. Briefly, NALM-6 cells were seeded into six-well
plates at the concentration of 1×106 cells/well and incubated
with different concentrations of I3C for indicated hours.
NALM-6 cells were then harvested and washed twice with
PBS and fixed with 70 % ethanol. Then cells were treated
with 0.5 μg/ml RNase in PBS and incubated at 37 °C for
30 min before staining with 50 μg/ml PI for 30 min. The cells
were analyzed using a FACScan flow cytometer (Becton
Dickinson).
Phosphatidylserine externalization (annexin-V assay)
NALM-6 cells were treated with doxorubicin in the presence or
absence of different concentrations of I3C for 24 h and were
then washed with PBS after the incubation time. A total of 1×
106 cells per sample were resuspended in a total volume of
100 μl of the incubation buffer. Annexin-V-Flous (2 μl per
sample) was added, and cell suspensions were incubated for
20 min in the dark. Fluorescence was then measured using flow
cytometery. The data were evaluated using the CellQuest
Software (Becton Dickinson) and expressed as percentage of
the cells positive for annexin-V (early apoptotic phase).
RNA purification, reverse transcription, and real-time PCR
amplification
Total RNAwas isolated from the cells using TriPure isolation
reagent (Roche), according to the manufacturer’s instructions.
One microgram RNA was used to prepare cDNA using the
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RevertAid First Strand cDNA Synthesis kit from Fermentas.
The cDNA prepared was subjected to quantitative reverse-
transcriptase polymerase chain reaction (qRT-PCR), using
Maxima SYBR green master mix (Fermentas) in the Rotor
Gene 6000 Real Time PCR System (Corbett Research,
Hilden, Germany). DNA was amplified in a 40-cycle PCR
reaction with the following conditions: denaturation at 95 °C
for 15 s, annealing and elongation at 60 °C for 60 s. The fold
induction or repression was measured relative to control and
calculated after adjusting for reference gene GAPDH. Each
sample was analyzed in triplicate, and representative data sets
are shown. Primer sequences are given as follows: PUMA
( f o r w a r d : g a c c t c a a c g c a c a g t a c g a g , r e v e r s e :
a g g a g t c c c a t g a t g a g a t t g t ) , NOXA ( f o r w a r d :
ccgtgtgtagttggcatctc, reverse: cccactcagcgacagagc), APAF-1
(forward: acaatgctctactacatgaaggatataaaga, reverse:
c ac tggaagaagagacaacaggaa ) , hTERT ( fo rwa rd :
atgcgacagttcgtggctca, reverse: atcccctggcactggacgta),
GAPDH (forward: gaaggtgaaggtcggagtc, reverse:
gaagatggtgatgggatttc).
Western blot analysis
Cells were centrifuged at different time points after various
treatments, and cellular pellets were washed with cold PBS
and lysed (5×106 cells/aliquots) in 0.2 ml of RIPA buffer
(10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA,
1 % Triton X-100, 0.1 % sodium dodecyl sulfate, and 0.5 %
sodium deoxycholate) containing protease and phosphatase
inhibitor cocktails (Sigma). After centrifugation at 13,000×g
for 20 min at 4 °C, the supernatant was collected. Protein
concentrations were determined by Bradford protein assay,
and equivalent amounts of total cellular protein were separat-
ed by 10 % SDS-PAGE, according to the method of Laemmli.
The gels were then electroblotted onto nitrocellulose mem-
branes (Hybond-ECL, Amersham Corp.). Subsequently,
membranes were blocked with 5 % nonfat dry milk in TBS
containing 0.1 % (v/v) Tween-20 for 1 h at room temperature
and probed with specific primary antibodies overnight at 4 °C.
After five washes in TBS-T, membranes were incubated with
HRP-conjugated secondary antibodies. Proteins were then vi-
sualized with a chemiluminescence detection system
(Amersham ECL Advance Kit , GE Heal thcare) .
Densitometric quantificationwas done using ImageJ software.
Nuclear fractionation and NF-κB p65 DNA-binding activity
assay
The preparation of nuclear extracts was performed using the
Nuclear Extract Kit (ActiveMotif, Carlsbad, CA) according to
manufacturer’s instructions. The DNA-binding activity of
NF-κB was quant i f ied in the NALM-6 cel ls by
TransAMTM NF-κB p65 Transcription Factor Assay Kit
(Active Motif, TransAM® NFκB p65, #40096) according to
the manufacturer’s instructions. Briefly, 5 μg of the nuclear
extracts was incubated in 96-well plates coated with
immobilized oligonucleotide (5′-AGTTGAGGGGACTTTC
CCAGGC-3′) containing a consensus (5′-GGGACTTTCC-
3′) binding site for the p65 subunit of NF-κB for 1 h. NF-κB
binding to the target oligonucleotide was detected by incuba-
tion with primary antibody specific for p65 subunit. HRP-
conjugated secondary antibodies were used for the detection
of p65 bound to the target oligonucleotides. For quantification
of NF-κB activity, the optical densities were measured at
450 nm by a microplate reader.
Statistical analysis
Data were analyzed using a two-tailed Student’s t test. A P
value of <0.05 was considered statistically significant.
Results
I3C induces cell-growth inhibition, G1 cell-cycle arrest,
and apoptosis in NALM-6 cells
To test the effects of I3C on cell growth, we treated NALM-6
cells with 20, 30, 40, 50, and 60 μM I3C for 24 and 48 h. It is
well known that actively proliferating cells increase their met-
abolic activity. In Fig. 1a, we show I3C’s dose-dependent
inhibition of metabolic activity of NALM-6 cells. Inhibition
of cell proliferation could be the result of the induction of
apoptosis or cell cycle growth arrest. To determine whether
the inhibitory effects of I3C on cell proliferation could be
attributed to alterations in the cell cycle, NALM-6 cells were
treated with different concentrations of I3C for 24 h and sub-
jected to cell cycle analysis by flow cytometry. We found that
in NALM-6 cells, increasing concentrations of I3C induced
the percentage of G1 phase cells (Fig. 1b). Moreover, to as-
certain whether the cell death induced by I3C could be apo-
ptosis, we investigated the cleavage of poly (ADP-ribose) po-
lymerase (PARP) or activation of caspase-3, caspase-7, and
caspase-9 by western blotting after treatment of NALM-6
cells with different concentrations of I3C for 24 and 48 h.
As shown in Fig. 1c, I3C alone activated these caspases
and cleaved PARP at maximal concentration (60 μM)
obviously after 48 h, and to a lesser extent after 24 h.
Caspase activation and PARP cleavage were also ob-
served with lower concentration of I3C (40 μM) treat-
ment for 48 h. Collectively, these results provide evi-
dence that the cell death induced by I3C is caused by
cell cycle arrest and caspase-mediated apoptosis.
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I3C induces p53 accumulation and expression
of pro-apoptotic p53 target genes
To further understand the molecular mechanism of I3C-
induced apoptosis, western blot analysis was performed to
study the effect of I3C treatment on the p53 tumor suppressor
protein. To do so, NALM-6 cells harboring wild-type p53
were treated with a range of I3C concentrations (0–60 μM)
and cells were harvested after 24 and 48 h. p53 protein levels
were assessed using western blot analysis of cellular extracts.
As presented in Fig. 2a, I3C induced p53 protein levels after
24 and 48 h of treatment with 60 μM I3C producing the
highest fold induction of the concentrations tested. Protein
levels of the p53 downstream targets p21/waf1 and Bax were
also examined by western blot analysis. Treatment of cells
with 60 μM I3C resulted in only a modest increase in p21/
waf1 and Bax protein levels over control cells after 24 h
(Fig. 2a). However, the increase in p21/waf1 and Bax protein
levels was prominent after 48 h treatment with I3C 40 and
60 μM. To corroborate these results, we carried out qRT-
PCR assays and found that I3C increases mRNA levels of
p53-targeted proapoptotic genes including PUMA, NOXA,
and Apaf-1 (Fig. 2b). It is known that p53 is a powerful in-
hibitor of human telomerase reverse transcriptase (hTERT), a
key component for telomerase [22]. Indeed, using qRT-PCR,
it was shown that I3C repressed hTERT mRNA expression
levels in wild-type p53 expressing NALM-6 cells (Fig. 2b).
I3C represses antiapoptotic NF-κB target genes
The constitutive levels of several antiapoptotic NF-κB target
genes and the time course for the effect of I3C on expression
of these genes in NALM-6 cells were studied by western blot
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Fig. 1 Effects of I3C on cell proliferation and apoptosis in NALM-6
cells. a Cell proliferation assay of NALM-6 cells. Cells were grown in
complete medium with different concentrations of I3C in 96-well plates
for up to 24 and 48 h, and cell growth was measured by MTT assay. The
results are expressed as mean±SD of at least three independent
experiments.*P<0.05 compared to non-treated control cells. b I3C
caused cell cycle arrest at G1 phase. Cells were treated with I3C (20,
40, and 60 μM) for 24 h, and cell cycle analysis was performed by
flow cytometry. Data shown are representative of at least three
independent experiments.*P<0.05 compared to non-treated control
cells. c Effect of I3C on caspase activation and PARP cleavage. After
the treatment of cells with the indicated concentration of I3C for 24 and
48 h, total cell lysates were prepared and western blotting was performed
using antibodies specific to cleaved PARP-1, procaspase-3, caspase-9,
caspase-7, and β-actin. The asterisk represents a nonspecific band seen
using the caspase-9 antibody. The relative expression of cleaved PARP
protein was calculated by dividing the intensity of each band, quantified
using ImageJ, by the respective intensity of actin
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analysis. Cultures of NALM-6 cells were treated with a range
of I3C concentrations (0–60 μM) and the protein levels of
XIAP, c-Myc, cIAP-1, Bcl-xL, and Bcl-2 were assessed after
24 and 48 h. The levels of c-Myc, Bcl-xL, and Bcl-2 expres-
sion were down-regulated in NALM-6 cells treated with
60 μM concentration of I3C for 24 and 48 h (Fig. 3). The
protein expression levels of XIAP and c-IAP1 were reduced
after treatment of cells with 60 μM concentration of I3C for
48 h.
I3C potentiates doxorubicin-induced apoptosis
through caspase activation and PARP cleavage
To determine whether I3C could sensitize BCP-ALL cells to
chemotherapeutic drug doxorubicin, we examined the effect
of individual and combination treatment with I3C and doxo-
rubicin after 24 h exposure using the MTT assay. We
pretreated NALM-6 cells with escalating doses of I3C for
1 h and then with or without 125 nM dose of doxorubicin
for further 24 h. As indicated in Fig. 4a, combination of I3C
and doxorubicin caused greater inhibition of cellular prolifer-
ation than either drug alone. Next, induction of apoptosis was
assessed by the annexin-V-staining assay after treatment of
cells with doxorubicin and increasing concentrations of I3C
for 24 h. We found that I3C could sensitize NALM-6 cells to
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Fig. 2 I3C activates p53-mediated apoptosis pathway. a The effect of
I3C on the protein expression of p53, p21, and Bax. After the treatment of
cells with the indicated concentration of I3C for 24 and 48 h, total cell
lysates were prepared and western blotting was performed using
antibodies specific to p53, p21, Bax, and β-actin. b Modulation of p53
target genes by I3C. NALM-6 cells were treated with 60μM I3C for 48 h,
after which RNA was harvested, and expression of the indicated genes
was measured using quantitative RT-PCR and normalized to the
expression of GAPDH
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Fig. 3 Effect of I3C on the expression of NF-κB target genes. aNALM-
6 cells were treated with 20, 40, and 60 μM I3C for 24 and 48 h. Cell
lysates were prepared and western blot analysis was performed with
indicated antibodies (data from a representative experiment is shown
from a total of three independent experiments). b Densitometric
quantification was done with 60 μM concentration of I3C for 24 and
48 h. The relative expression of the proteins was calculated by dividing
the intensity of each band, quantified using ImageJ, by the respective
intensity of actin (n=3; *P<0.05, relative to untreated cells)
Fig. 4 Effects of co-treatment with I3C and doxorubicin on apoptosis in
NALM-6 cells. a NALM-6 cells were treated with increasing doses of
I3C with or without 125 nM doxorubicin (Dox) for 24 h, and the viability
of cells was assessed by the MTT assay (n=3; *P<0.05, relative to cells
treated with either Dox or I3C alone). b NALM-6 cells were treated for
24 h with 20, 40, and 60 μM I3C alone, 125 nM doxorubicin alone, or the
combinations. Apoptotic cells were quantified using annexin-V-FITC
staining and FACS analysis (n=3; *P<0.05, relative to cells treated
with either Dox or I3C alone). c The sub-G1 population was assessed
by flow cytometry after exposure to the indicated agents for 24 h. d
NALM-6 cells were exposed to the indicated agents for 8 or 24 h. The
cleavage of PARP and caspase-9 was analyzed by western blotting. β-
Actin was used as a loading control. The asterisk represents a nonspecific
band seen using the caspase-9 antibody
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doxorubicin in a dose-dependent manner (Fig. 4b). Identical
drug concentrations used for the annexin-V apoptosis assay
were used for cell cycle analysis by flow cytometry.
Treatment with increasing concentrations of I3C alone in-
creased the percentage of cells in G1 phase of cell cycle,
whereas doxorubicin induced a G2-M arrest in NALM-6 cells
(Fig. 4c). In addition, NALM-6 cells treated with combination
I3C and doxorubicin exhibited a significant increase in the
sub-G1 population indicative of apoptosis (Fig. 4c), consistent
with the elevated levels of apoptosis observed in annexin-V
assay. To confirm these results at the molecular level, we in-
vestigated the cleavage of PARP or activation of caspase-9 by
western blotting. It was already shown that I3C by itself had
no cytotoxic effect on NALM-6 cells at 40 μM concentration
and a minimal cytotoxicity (~10 %) at 60 μM after 24 h. As
presented in Fig. 4d, doxorubicin alone could induce only
modest PARP and caspase-9 cleavage, whereas in combina-
tion with I3C, it clearly cleaved PARP and caspase-9 to their
active forms. These data indicate that I3C significantly en-
hances the apoptotic effect of chemotherapeutic drug doxoru-
bicin in BCP-ALL cells.
I3C inhibits doxorubicin-induced NF-κB activation
in NALM-6 cells
A side effect of many commonly used chemotherapeutic
drugs is the activation of NF-κB, a potent inducer of
antiapoptotic genes, which may mediate the process of
chemoresistance in tumor cells [23]. In this study, we have
assessed the effect of doxorubicin, an anthracycline widely
used in the treatment of hematological cancers including acute
lymphoblastic leukemia, in the presence or absence of I3C on
NF-κB activation and expression of its downstream target
genes Bcl-2 and c-Myc in NALM-6 cells. To this end, cells
were pretreated with or without I3C 60 μM for 1 h followed
by treatment with doxorubicin 0.25 μM for 4 h, and then the
nuclear NF-κB p65 subunit expression and DNA binding
were analyzed utilizing western blot analysis and enzyme-
linked immunosorbent assay, respectively. As indicated in
Fig. 5a, treatment of NALM-6 cells with doxorubicin
0.25 μM resulted in an increase of basal NF-κB p65 DNA
binding activity in the nucleus that was markedly reduced in
the presence of I3C 60 μM. In order to confirm the results of
the p65 DNA binding activity, we also examined the effects of
doxorubicin treatment in the presence or absence of I3C on the
levels of nuclear p65 by western blot. Consistent with the
ELISA results of DNA binding activity, NALM-6 cells treated
with doxorubicin for 4 h had a significant increase in nuclear
p65 protein when compared to control cells (Fig. 5b). When
cells were pretreated with I3C, the ability of doxorubicin to
induce nuclear accumulation of NF-κB was inhibited
(Fig. 5b). The translocation of NF-κB to the nucleus is pre-
ceded by phosphorylation of IκBα and its proteolytic
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Fig. 5 I3C decreases the induction of NF-κB activity by doxorubicin. a
NALM-6 cells were treated with or without I3C 60 μM for 1 h before
treatment with doxorubicin. The cells were then harvested after 4 h and
nuclear fraction was separated using nuclear extraction kit. NF-κB
activity was quantified by enzyme-linked immunosorbent assay using
the TransAM NF-κB p65 Transcription Factor Assay Kit, according to
the manufacturer’s instructions. Values represent mean±SD from three
independent experiments. b NALM-6 cells were pretreated with I3C
60 μM for 1 h prior to adding doxorubicin. Four hours post treatment,
the nuclear extracts were collected to detect NF-κB p65 expression by
western blotting. cNALM-6 cells were pretreated with I3C 60μM for 1 h
prior to adding doxorubicin. After 4 h, the cytoplasmic extracts were
collected to detect IκBα and phospho-IκBα proteins by Western
blotting. d NALM-6 cells were treated with I3C 60 μM before addition
of doxorubicin and then harvested at the times indicate. Immunoblot
analysis was performed using specific antibodies against c-Myc and
Bcl-2. The figure shows one representative blot of three experiments
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degradation [24]. To determine whether I3C’s inhibitory ac-
tivity was due to inhibition of IκBα degradation, we
pretreated cells with I3C, exposed them to doxorubicin, and
examined them for IκBα and phospho-IκBα status by west-
ern blot analysis. The I3C-only treated cells showed a dramat-
ic decrease in phospho-IκBα (Fig. 5c). We found that doxo-
rubicin induced IκBα phosphorylation and its degradation,
but in I3C-pretreated cells, doxorubicin had no effect on
IκBα degradation (Fig. 2b). These results indicate that I3C
inhibits both doxorubicin-induced NF-κB activation and
IκBα degradation. In addition, the effect of doxorubicin in
the presence or absence of I3C on the expression of two
known NF-κB target genes, Bcl-2 and c-Myc, was assessed.
To this end, cells were pretreated with or without I3C 60 μM
for 1 h followed by treatment with doxorubicin 0.25 μM for 8
and 24 h. Cells were then harvested and cellular extracts were
evaluated by western blot for the protein levels of Bcl-2 and c-
Myc. Exposure to 0.25 μM doxorubicin decreased c-Myc
protein expression below constitutive level after 24 h
(Fig. 5d). However, c-Myc protein level was further reduced
in the presence of I3C. Moreover, the levels of Bcl-2 protein
were markedly increased in response to doxorubicin after 24 h
that was potently inhibited in the presence of I3C (Fig. 5d).
Our results show, when doxorubicin and I3C were combined,
c-Myc and Bcl-2 protein levels were substantially decreased,
suggesting that I3C can modulate NF-κB target genes through
inhibition of NF-κB activity.
Discussion
Emerging evidence suggests that plant-derived dietary com-
pounds and supplements are potential sources of chemicals
with anticancer properties that might be combined with che-
motherapy or radiotherapy for the more effective treatment of
cancer [25–27]. I3C, a naturally occurring component of
Brassica vegetables such as cabbage, broccoli, and Brussels
sprouts, has been shown to reduce the incidence of spontane-
ous and carcinogen-induced tumors in vivo, and to inhibit the
growth of different types of human cancer cells in vitro
[28–30]. Recent studies suggest that I3C and its derivatives
that prevent cancer may enhance the efficacy of cancer thera-
peutics through altering the activity of key cell proliferation
and survival pathways [18]. Additionally, numerous cell cul-
ture, animal, and human studies have demonstrated I3C’s
safety and tolerability [31, 32]. There is a lot of evidence
showing that I3C may find potential application as an adjunc-
tive agent in cancer chemotherapy. Takada et al. showed that
I3C (50 μM) potentiates TNF-induced apoptosis through sup-
pression of NF-κB in human acute T cell leukemia Jurkat cell
line [33]. In another study, it was shown that I3C (100 μM)
enhanced gemcitabine-induced cytotoxicity in pancreatic
cancer cells [34]. Furthermore, I3C (100 μM) and tamoxifen
have been shown to act cooperatively to inhibit the growth of
ER+ breast cancer cells [35]. Nakamura et al. found that com-
bination of I3C (300 μM) and genistein synergistically in-
duces apoptosis in human colon cancer HT-29 cells [36]. In
our study, we used 60 μM concentration of I3C to suppress
NF-κB and potentiate doxorubicin-induced apoptosis in
NALM-6 cells.
We observed that I3C inhibited the growth of BCP-ALL-
derived cell line NALM-6 in a time- and dose-dependent man-
ner. The inhibition of cell growth found in I3C-treated cells
may be due to induction of G1 cell cycle arrest as a result of
up-regulated p21 expression levels. In agreement with the
effect on p21, we found that I3C increases p53 protein expres-
sion (Fig. 2a). Since p21 expression is directly induced by the
wild-type p53 protein [37], increased p21 expression appears
to be dependent of p53 regulation in I3C-treated NALM-6
cells. The growth inhibitory effect of I3C could also be direct-
ly related to its ability to down-regulate c-Myc, which is one
of the critical molecules required for cell growth and prolifer-
ation [38]. We showed that the expression of c-Myc was
down-regulated by I3C in NALM-6 cells. Grinkevich et al.
have shown in a recent study that p53 ablates c-Myc expres-
sion by several mechanisms [39]. Therefore, the up-regulation
of p53 induced by I3C may be important in the subsequent
down-regulation of c-Myc. It is well established that p53 plays
a critical role in protecting against cancer through modulation
of various cellular processes including apoptosis, cell cycle
arrest, and DNA repair [40]. Mutational inactivation of p53
tumor suppressor gene confers resistance to the chemoradia-
tion therapy that kills cancer cells through apoptotic pathways
[41]. Interestingly, TP53 mutations are detected in less than
5 % of pediatric ALL tumors at diagnosis [42, 43]. Given the
fact that most cases of BCP-ALL harbor wild-type p53, acti-
vation of the p53 pathway by natural dietary agents such as
I3C in human ALL cells could be a promising strategy to
improve chemotherapy. hTERT is the key component of the
human telomerase complex that controls telomerase activity
[44]. hTERT expression is repressed in most normal human
somatic cells, but high levels of its expression and activity are
found in the majority of human tumors [45]. Recent studies
have shown that hTERT expression is down-regulated upon
activation of wild-type p53 [46]. Notably, it appears that p53-
mediated down-regulation of hTERT is important for efficient
p53-dependent apoptosis [47]. Moreover, previous studies
have demonstrated that the hTERT gene is a direct transcrip-
tional target of c-Myc [48, 49]. Thus, the most straightforward
interpretation of our results is that I3C-induced p53 up-
regulation and c-Myc down-regulation may contribute in sup-
pression of hTERT expression in NALM-6 cells.
It has been reported that NF-κB is constitutively active in
over 90 % of childhood ALL and that the active NF-κB me-
diates cell survival [16]. In our study, we found that I3C down-
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regulates basal activity of NF-κB in NALM-6 cells as shown
by decrease in the DNA-binding activity of p65. Our result is
consistent with a report by Chinni et al., who showed the
suppression of constitutive NF-κB by I3C in PC3 cells [50].
We demonstrated that I3C also inhibited NF-κB-regulated
gene products involved in antiapoptosis (IAP1, XIAP, Bcl-2,
Bcl-xL) (Fig. 6). Intriguingly, NF-κB is activated in B cell
precursor acute lymphoblastic leukemia by treatment with
anthracyclines or by ionizing radiation [51]. However, phar-
macologic inhibition of NF-κB restores or enhances sensitiv-
ity of primary ALL cells to anthracycline-induced apoptosis
[52]. Our findings also showed that I3C in combination with
doxorubicin was significantly associated with the inhibition of
cell proliferation and induction of apoptosis that could be due
to the inhibition of nuclear NF-κB p65 expression and NF-κB
DNA-binding activity. It has been reported that BCP-ALL
cells accumulate high levels of Bcl-2 protein expressionwhich
appears to endow lymphoblasts with survival advantage [53].
Furthermore, recent work from the Letai group [54] has indi-
cated Bcl-2 dependency of ALL cells, suggesting the potential
ability of Bcl-2 antagonists for improving current ALL thera-
py. Interestingly, we observed that doxorubicin up-regulated
Bcl-2 protein levels in BCP-ALL-derived cell line NALM-6
which was inhibited in the presence of I3C. This finding sup-
ports this idea that I3C alone or in combination with
anthracyclines may be a useful and novel strategy for the
prevention of Bcl-2 expression in BCP-ALL cells.
In summary, we demonstrated that I3C inhibited cell pro-
liferation and induced apoptosis in BCP-ALL cells by simul-
taneously modulating the p53 and NF-κB signaling pathways.
Our results showed that combination of lower dose of doxo-
rubicin with a natural nontoxic dietary compound (I3C) en-
hances the inhibition of cell growth and the induction of apo-
ptosis in NALM-6 cells through inhibition of the NF-κB.
Given the pharmacologic safety of I3C, our study suggest that
combination of this compound with existing agents will allow
a lower dose of chemotherapeutic drugs to be used and thus
will decrease nonspecific toxicity of drugs in treatment of
BCP-ALL. However, further investigation, including clinical
trials, is needed to prove or disprove the usefulness of I3C as
either single agent or in combination for the treatment of BCP-
ALL.
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